Technology platforms create strategic opportunity.

Market Context

Regulatory tailwinds favor validated alternatives.

The FDA reclassified vaporized hydrogen peroxide sterilization to Category A in January 2024, formally recognizing VHP as an established sterilization method alongside steam, dry heat, and ethylene oxide. Simultaneously, ISO 22441 established the international consensus standard for VHP validation — referenced by the FDA, EU Notified Bodies under MDR 2017/745, Health Canada, and regulatory authorities across Asia-Pacific.

EPA mandates requiring 90% reduction in ethylene oxide emissions are compressing transition timelines in the United States. In the European Union, the combination of stricter MDR requirements and a harmonized ISO 22441 standard creates a parallel pathway for VHP adoption. The demand for validated VHP systems — and the institutional expertise to deploy them — is structural, global, and accelerating.

These shifts are not predictions — they are documented regulatory actions with compliance deadlines across multiple jurisdictions. PuroGen's existing, validated systems are positioned at the intersection of this transition. For strategic partners, the opportunity is to leverage a technology portfolio that was designed for this standard before it existed — with documentation structured for multi-market regulatory submissions.